This Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) provides $730,000 in funding to Human Cell Co for the development of a novel nerve growth factor (NGF) therapy called HC201 for the treatment of dry eye disease (DED). The key products and services to be delivered include: Determining the efficacy and mechanism of action of topical HC201 in improving tear film production and corneal sensitivity in a mouse model of corneal nerve...
This Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) provides $615,979.00 to investigate a promising peptide-based combination therapy to prevent and treat diabetes-induced damage to the cornea. The project aims to: 1) establish the therapeutic role of TB4 and VIP as a combination treatment against diabetic corneal complications, and 2) elucidate the DDR-TRP axis under hyperglycemic conditions. The research will involve in vitro...
This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), provides funding of $294,662 to Proteris Biotech, Inc. to support research on using the protein Clusterin (CLU) to treat ocular surface disease and dry eye. The project aims to determine whether CLU can protect the ocular surface epithelia from damage and also have an anti-inflammatory effect in dry eye disease. Recombinant human CLU will be tested for efficacy in a mouse...
This $332,179 Project Grant awarded by the National Eye Institute (CFDA 93.867 Vision Research) supports the development of nanobarrier contact lenses that can provide sustained delivery of the drug cysteamine to treat the ocular complications of cystinosis. The lenses are designed to replace the current 8-times daily eye drop regimen, improving patient compliance and reducing side effects from the preservatives and acidic pH in the eye drops. The project aims to demonstrate the lenses can...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), provides $356,485 to Stellular Bio, Inc. to scale up manufacturing and support chemistry, manufacturing, and control (CMC) and toxicology studies for their STLR-201 regenerative therapeutic for Sjögren's syndrome-related dry eye disease. The project aims to finalize the drug substance processing strategy, scale up production, and conduct GMP manufacturing to enable...
The National Eye Institute (NEI) awarded a $590,172 Project Grant under the Vision Research federal grant program (CFDA 93.867) to Vyluma Inc. to develop a safe and effective topically administered pharmacotherapy to treat acute corneal pain. The key products and services to be delivered under this grant include: 1) Pharmacodynamic dose identification studies in a rat model to determine the minimum effective dose of the topical pregabalin formulation NVK032 for treating acute corneal pain; 2)...
The National Eye Institute (NEI) awarded a $674,963 Project Grant (CFDA 93.867 - Vision Research) to Microbiotix, Inc. to advance the development of filociclovir (FCV) as a treatment for adenoviral conjunctivitis and acute keratoconjunctivitis. The 3-year project aims to complete formulation development, conduct IND-enabling preclinical toxicology studies, and finalize regulatory requirements to support an Investigational New Drug (IND) submission for FCV to treat these ocular adenoviral...
The National Eye Institute (NEI) awarded Revopsis Therapeutics, Inc. a $933,533 Project Grant under the Vision Research program (CFDA 93.867) to advance the development of their first-in-class RO-104 trispecific surrobody treatment for retinal diseases. RO-104 simultaneously targets three key angiogenic factors - VEGF-A, VEGF-C, and Ang-2 - that contribute to vision loss in conditions like age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. The award will fund...
The National Eye Institute (NEI) awarded a $412,285 Project Grant under the Vision Research program (CFDA 93.867) to Oregon Health & Science University (OHSU) to validate an advanced transepithelial corneal collagen crosslinking (CXL) technology. The goal is to develop a more effective CXL procedure that can strengthen the cornea without requiring removal of the surface epithelium, which often leads to complications. The key products and services to be delivered include: Constructing an...
This Project Grant award by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $583,250 to The Schepens Eye Research Institute, Inc. to identify the mechanisms underlying ocular toxicity caused by nitrogen mustard exposure and evaluate specialized lipid mediators as potential medical countermeasures. The key objectives are to: 1) Determine how nitrogen mustard alters the function of conjunctival goblet cells and if...